Sugi Predict

Sugi Predict / Compounds / Bromobenzene

Bromobenzene

Bromobenzene

SCHEMBL260618

Brc1ccccc1.F[B-](F)(F)F.N#[NH+]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ MAPK1 P28482 2/20 0.50
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2A6 P11509 1/20 0.37
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ AKR1C3 P42330 2/20 0.34
▸ NR1H4 Q96RI1 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromobenzene SCHEMBL260235 0.91 ALDH1A1 (0.73) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL28830047 0.91 ALDH1A1 (0.73) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL9893634 0.88 ALDH1A1 (0.69) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL27592660 0.88 ALDH1A1 (0.69) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL28540774 0.83 ALDH1A1 (0.61) ALDH1A1TDP1MAPK1NPC1RAB9A
Biphenyl SCHEMBL28211636 0.79 ALDH1A1 (0.60) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL259850 0.78 — —
Bromobenzene SCHEMBL537562 0.78 ALDH1A1 (1.00) ALDH1A1TDP1MAPK1NPC1RAB9A
Bromobenzene SCHEMBL1331176 0.78 — —
Bromobenzene SCHEMBL20537325 0.78 ALDH1A1 (1.00) ALDH1A1TDP1MAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12529695-B2 Fentanyl analogue detection methods and kits thereof VERITEQUE USA, INC. (US) 2026-01-20 — — US claimed
US-20220390439-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF VERITEQUE USA, INC. 2022-12-08 — — US claimed
EP-4049008-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF Veriteque USA, Inc. (US) 2022-08-31 — — EP claimed
CN-113121318-B Biheteroaromatic hydrocarbon compound and preparation method thereof 浙江工业大学 2022-04-26 — — CN claimed
EP-3586377-B1 DEVICE AND REALIZATION METHOD OF LUMINESCENT SOLAR CONCENTRATORS BASED ON SILICON NANOSTRUCTURES UNIV BOLOGNA ALMA MATER STUDIORUM (IT) 2021-07-28 — — EP claimed
CN-113121318-A Biheteroaromatic hydrocarbon compound and preparation method thereof 浙江工业大学 2021-07-16 — — CN claimed
CN-112724979-A Oil-soluble quantum dot water-dispersed fluoborate phase transfer method 南开大学 2021-04-30 — — CN claimed
WO-2021081063-A1 FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF VERITEQUE USA, INC. (US) 2021-04-29 — — WO claimed
CN-111777559-A Method for preparing polysubstituted pyrazole based on terminal alkyne 苏州大学 2020-10-16 — — CN claimed
US-20200058814-A1 DEVICE AND REALIZATION METHOD OF LUMINESCENT SOLAR CONCENTRATORS BASED ON SILICON NANOSTRUCTURES ALMA MATER STUDIORUM - UNIVERSITÁ DI BOLOGNA (IT) 2020-02-20 — — US claimed
CN-110256349-A Polysubstituted pyrazoles and process for their preparation 苏州大学 2019-09-20 — — CN claimed
CN-103466591-A Method for selectively eliminating metallic carbon nanotubes in commercial carbon nanotubes, and its application SUZHOU INST NANO TECH & NANO B 2013-12-25 — — CN claimed
WO-2002066092-A2 DRUG ELUTING DEVICE FOR TREATING VASCULAR DISEASES ANGIOGENE INC. (CA) 2002-08-29 — — WO claimed
US-20020119178-A1 Drug eluting device for treating vascular diseases LEVESQUE LUC (CA) 2002-08-29 — — US claimed
US-12529695-B2 Fentanyl analogue detection methods and kits thereof VERITEQUE USA, INC. (US) 2026-01-20 — — US disclosed
CN-119185207-A Amphiphilic polymers and their use for improved production of nanoparticles for antigen-targeted delivery TOPAS医疗科技有限公司 2024-12-27 — — CN disclosed
CN-117088861-A 2-substituted aryl-oxazolin-4-one derivative and application thereof 浙江大学 2023-11-21 — — CN disclosed
CN-103466591-A Method for selectively eliminating metallic carbon nanotubes in commercial carbon nanotubes, and its application SUZHOU INST NANO TECH & NANO B 2013-12-25 — — CN disclosed
US-8133549-B2 Method for modifying insulating or semi-conductive surfaces, and resulting products ALCHIMER (FR) 2012-03-13 — — US disclosed
US-20090301862-A1 METHOD FOR MODIFYING INSULATING OR SEMI-CONDUCTIVE SURFACES, AND RESULTING PRODUCTS ALCHIMEDICS (FR) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529695-B2 Fentanyl analogue detection methods and kits thereof CA13, CA2, CA12 ALDH1A1 1513/4885TDP1 4537/4885MAPK1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.